At 8.1% CAGR, the Asia Pacific Benign Prostatic Hyperplasic Devices Market is projected to be worth US$ 771.09 million by 2028, says Business Market Insights   

According to Business Market Insights’ research, the Asia Pacific benign prostatic hyperplasic devices market was valued at US$ 484.08 million in 2022 and is expected to reach US$ 771.09 million by 2028, registering an annual growth rate of 8.1% from 2022 to 2028. Growing investments, funds, and grants for research in BPH treatment and higher product approvals and launches.                

Players operating in the benign prostatic hyperplasic devices industry focus on investing high amounts in the development of advanced surgical technologies as alternatives to conventional techniques. Advanced devices enabled with new technologies help provide immediate relief and reduce morbidity. Several recent developments have taken place in the recent years such as: In June 2021, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by BPH or enlarged prostate, declared the completion of its Series B funding round with a total of US$ 24 million. The investment was led by Invus Opportunities and included participation from Medical Technology Venture Partners, F-Prime Capital, CloudStone Capital, Astia Angels, Golden Seeds, SV Tech Ventures, etc. Further, In June 2021, Procept Biorobotics raised US$ 85 million to commercialize the AquaBeam system as a global BPH treatment. With this product, the company intends to make an impact with its water-based robotic technology in the field of prostate surgery. The series G financing was led by Fidelity Management & Research Company, with additional backing from T. Rowe Price Associates, CPMG, Perceptive Advisors, Viking Global Investors, and Duquesne Family Office. Also, In July 2019, Medeon Biodesign, Inc, a publicly traded Taiwan medical device company, announced that it recently led and closed an investment in Prodeon. Prodeon is a Taiwan-based company offering a simple, office-based treatment option for patients who need quick relief from LUTS caused due to BPH. The rise in such investments, funds, and grants for research in the field of BPH treatments is bolstering the benign prostatic hyperplasic devices market growth.

On the contrary, limiting awareness about prostate health among men. 

• Based on product, the Asia Pacific benign prostatic hyperplasic devices market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment held 34.5% market share in 2022, amassing US$ 167.02 million. It is projected to garner US$ 263.23 million by 2028 to expand at 7.9% CAGR during 2022–2028.
• Based on procedure type, the Asia Pacific benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held 28.9% market share in 2022, amassing US$ 139.81 million. It is projected to garner US$ 230.21 million by 2028 to expand at 8.7% CAGR during 2022–2028.
• Based on end user, the Asia Pacific benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held 41.3% market share in 2022, amassing US$ 200.07 million. It is projected to garner US$ 315.44 million by 2028 to expand at 7.9% CAGR during 2022–2028
• Based on country, the Asia Pacific benign prostatic hyperplasic devices market has been segmented into China, Japan, India, Australia, South Korea, and Rest of Asia Pacific.  Our regional analysis states that China captured 27.5% market share in 2022. It was assessed at US$ 133.06 million in 2022 and is likely to hit US$ 217.17 million by 2028, exhibiting a CAGR of 8.5% during the forecast period.  

Key players dominating the Asia Pacific benign prostatic hyperplasic devices market are KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH among others.

• In September 2021, Olympus was selected to exhibit the iTind device, a temporarily implanted device for the relief of enlarged prostate symptoms, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange virtually from September 21-23.  

• In May 2022, Teleflex Incorporated received National Medical Products Administration (NMPA) approval for its UroLift System in China for treating benign prostatic hyperplasia (BPH).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com